

## FOR IMMEDIATE RELEASE

Company Name Kyowa Hakko Kirin Co., Ltd.  
Representative Masashi Miyamoto, President and COO  
(Code No.4151, First Section of TSE)  
Inquiries Tomoko Kashiwabara, Director,  
Corporate Communications Department  
Media Contact: +81-3-5205-7205  
Investor Contact: +81-3-5205-7206

## Notice Regarding Change of Trade Name, Partial Amendments to the Articles of Incorporation, and Change of Location of Head Office

**Tokyo, July 31, 2018** – Kyowa Hakko Kirin Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and COO: Masashi Miyamoto; hereinafter, “Kyowa Hakko Kirin” or the “Company”) hereby announces that, at a meeting held on July 31, 2018, the Board of Directors resolved to submit a proposal at the 96th Ordinary General Meeting of Shareholders, to be held in March 2019, to change its trade name and partially amend its Articles of Incorporation.

Furthermore, Kyowa Hakko Kirin also announces that it was decided at the same meeting to change the location of the Company’s head office in conjunction with the change of trade name.

### 1. Change of trade name

#### (1) Reason for change

Kyowa Hakko Kirin has been steadily deploying initiatives aimed at evolving into a global specialty pharmaceutical company, and as global strategic products are steadily being developed and brought to market, it has been accelerating the business overseas.

Most of the Kyowa Hakko Kirin Group’s pharmaceutical group companies in the U.S. and Europe have already changed their names to Kyowa Kirin in 2016, and Kyowa Hakko Kirin believes changing its trade name will cultivate a greater sense of unity among the Group’s operation, promote the Kyowa Kirin brand on a worldwide basis and accelerate the Company’s realization as a global specialty pharmaceutical company.

#### (2) New trade name

KYOWA KIRIN KABUSHIKI KAISHA (“Kyowa Kirin Co., Ltd.” in English)

#### (3) Date of change

July 1, 2019

The Company plans for the Group’s overseas pharmaceutical group companies currently using the “Kyowa Hakko Kirin” name, which are mostly located in Asia, to also change their names to Kyowa Kirin as soon as the necessary preparations are in place.

### 2. Partial amendments to the Articles of Incorporation

#### (1) Reason for amendments

As stated in “1. Change of trade name, (1) Reason for change,” the Company plans to amend Article 1 of its current Articles of Incorporation. The effective date of this amendment to the Articles of Incorporation will be July 1, 2019.

(2) Details of amendments

The following table shows the current Articles of Incorporation and proposed Articles of Incorporation after amendments. Underlined parts are planned to be amended.

Current Articles of Incorporation	Proposed Articles of Incorporation after amendments
Article 1. (Trade name) The Company shall be called <u>KYOWA HAKKO KIRIN KABUSHIKI KAISHA</u> , which shall be expressed in English as <u>Kyowa Hakko Kirin Co., Ltd.</u>	Article 1. (Trade name) The Company shall be called <u>KYOWA KIRIN KABUSHIKI KAISHA</u> , which shall be expressed in English as <u>Kyowa Kirin Co., Ltd.</u>

**3. Change of location of head office**

As the headquarter functions were relocated to the new office in July 2016, the location of head office will be changed in conjunction with the change in the trade name. As part of this, procedures will be carried out to change the location of the marketing supervisor-general of pharmaceuticals, etc. as well as to change the location of the head office that is stated on product packaging and package inserts.

Present location of head office: 1-6-1 Otemachi, Chiyoda-ku, Tokyo

Location of head office after change: 1-9-2 Otemachi, Chiyoda-ku, Tokyo

End